Trial Profile

A Phase 1 clinical study of risperidone an ultra-long-acting oral therapy to treat schizophrenia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risperidone (Primary)
Indications Schizophrenia
Focus Adverse reactions
Sponsors Lyndra

Most Recent Events

18 Feb 2020 New trial record
11 Feb 2020 According to an Lyndra Therapeutics media release, the company has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for its ultra-long-acting oral therapy to treat schizophrenia (risperidone). Following IND approval, the company plans to initiate multiple Phase I studies in 2020 and beyond.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com